ZURICH (Reuters) – Swiss biotech group Idorsia on Friday lifted the lid off a 2019 deal for its investigational epilepsy medicine, revealing the pact that is potentially worth more than $400 million is with U.S.-based Neurocrine Biosciences.
Last year, Idorsia got a $5 million payment for a licensing option for ACT-709478, but kept Neurocrine’s identity a secret.
Their agreement calls for Idorsia to get $45 million in cash, $7 million for research and up to $365 million in development and regulatory milestone payments if Neurocrine exercises its option within 30 days of the U.S. Food and Drug Administration’s accepting an investigational new drug application that is now expected for mid-2020.
Royalties are also in the offing if ACT-709478 makes it to market.
Idorsia Chief Executive Jean-Paul Clozel is striking agreements with partners like Neurocrine, a small drugmaker based in San Diego, for some of his pipeline’s dozen investigational medicines.
He is augmenting his…
Source news reuters.com, click here to read the full news.
